Drugs / DWP05195
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01094834 | Apr → Oct 2010 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT00969787 | Apr → Nov 2009 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01557010 | Mar 2012 → Nov 2013 | postherpetic neuralgia | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2011-07-04 | Daewoong Pharmaceutical Co. LTD. | Regulatory Acceleration to develop neuropathic pain killer daewoong.co.kr ↗
Daewoong Pharmaceutical Co., Ltd (President Lee Jong Wook) has announced that ‘DWP05195,’ a neuropathic pain killer, has been approved for asecond clinical test. |
| 2011-07-04 | Daewoong Pharmaceutical Co. LTD. | Results Completed 1st clinical test of the first neuropathic pain killer developed in Korea daewoong.co.kr ↗
Daewoong Pharmaceutical Co., Ltd (President Lee Jong Wook) has successfully completed the 1st clinical test of ‘DWP05195,’ the first neuropathic painkillerdeveloped in Korea. |
| 2010-07-23 | Daewoong Pharmaceutical Co. LTD. | Regulatory Next generation pain killers ‘DWP05195’, obtained approval of multiple medication clinical trial plans daewoong.co.kr ↗
Daewoong Pharmaceutical (CEO: Jong Wook Lee) acquired the approval of multiple medication tests from KFDA (Korean Food and Drug Administration), after completing the single medication phase 1 study about chronic intractable painkillers ‘DWP05195’ successfully. |
| 2009-03-17 | Daewoong Pharmaceutical Co. LTD. | Regulatory Next generation pain killer enters into clinical trial daewoong.co.kr ↗
Daewoong Pharmaceutical (CEO: Jong Wook Lee) has received approval from the KFDA (Korean Food and Drug Administration) to enter into clinical trials for a next generation neural pain killer: DWP05195. |
| 2009-02-05 | Daewoong Pharmaceutical Co. LTD. | Regulatory Clinical trial application submitted for a next generation pain killer. daewoong.co.kr ↗
Daewoong Pharmaceutical has submitted an application to conduct clinical trials for a newly developed next generation neural pain killer. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2011-07-04 | Daewoong Pharmaceutical Co. LTD. | Acceleration to develop neuropathic pain killer daewoong.co.kr ↗ |
| 2011-07-04 | Daewoong Pharmaceutical Co. LTD. | Completed 1st clinical test of the first neuropathic pain killer developed in Korea daewoong.co.kr ↗ |
| 2010-07-23 | Daewoong Pharmaceutical Co. LTD. | Next generation pain killers ‘DWP05195’, obtained approval of multiple medication clinical trial plans daewoong.co.kr ↗ |
| 2009-03-17 | Daewoong Pharmaceutical Co. LTD. | Next generation pain killer enters into clinical trial daewoong.co.kr ↗ |
| 2009-02-05 | Daewoong Pharmaceutical Co. LTD. | Clinical trial application submitted for a next generation pain killer. daewoong.co.kr ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DWP05195 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01094834 ↗ |
| Action | Inhibit | “Vanilloid receptor antagonist” CHEMBL5314400 ↗ |
| Modality | Small molecule | — CHEMBL5314400 ↗ |
| Route | Oral | “tablets, oral administration” NCT00969787 ↗ |
| Target | TRPV1 | “Vanilloid receptor antagonist” CHEMBL5314400 ↗ |